LENMELDY (atidarsagene autotemcel)

Office-Administration – intravenous (IV) infusion

Diagnosis considered for coverage:

Metachromatic Leukodystrophy (MLD): Indicated for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ) metachromatic leukodystrophy (MLD).

Coverage Criteria:

 

For diagnosis of MLD:

  • Diagnosis of metachromatic leukodystrophy (MLD); AND
  • Molecular genetic testing confirms mutation in the arylsulfatase A (ARSA) gene; AND 
  • Disease is one of the following: 
    • Pre-symptomatic late infantile (PSLI) as confirmed by both of the following: 
      • Disease onset at less than or equal to 30 months of age, and 
      • One of the following: 
        • Absence of neurological signs and symptoms of MLD (e.g., peripheral neuropathy, gait difficulties, hypotonia) 
        • Abnormal reflexes or abnormalities on brain magnetic resonance imaging (MRI) and/or nerve conduction tests not associated with functional impairment (e.g., no tremor, no peripheral ataxia) OR
    • Pre-symptomatic early juvenile (PSEJ) as confirmed by both of the following: 
      • Disease onset at greater than 30 months and less than 7 years of age, and 
      • One of the following: 
        • Absence of neurological signs and symptoms of MLD (e.g., peripheral neuropathy, gait difficulties, hypotonia) 
        • Abnormal reflexes or abnormalities on brain magnetic resonance imaging (MRI) and/or nerve conduction tests not associated with functional impairment (e.g., no tremor, no peripheral ataxia) OR
    • Early-symptomatic early juvenile (ESEJ) as confirmed by all of the following: 
      • Disease onset at greater than 30 months and less than 7 years of age 
      • Gross motor function classification (GMFC)-MLD score less than or equal to 1 
      • Intelligence quotient (IQ) of greater than or equal to 85; AND
  • Prescribed by a specialist with expertise in MLD at an authorized treatment center; AND
  • Both of the following: 
    • Patient has never received Lenmeldy treatment in their lifetime 
    • Patient has never received prior hematopoietic stem cell transplant (HSCT)
Coverage Duration:
  • 1 time authorization in lifetime
Dosing:

For diagnosis of MLD:

  • Administration consists of HSC mobilization & apheresis, manufacturing (transduction), myeloablative conditioning, infusion, and post-administration (engraftment)
  • Dose is based on MLD subtype and child’s weight at the time of infusion: 
    • PSLI (4.2 to 30 X 106 CD34+ cells/kg)
    • PSEJ (9.0 to 30 X 106 CD34+ cells/kg)
    • ESEJ (6.6 to 30 X 106 CD34+ cells/kg)
Authorization is not covered for the following:
  • The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.
Additional Information: 
  • MLD is a rare inherited lysosomal storage disease due to a deficiency in the arylsulfatase A [ARSA] enzyme resulting in the accumulation of sulfatides, leading to neurodegeneration.
  • Lenmeldy is the first FDA-approved therapy for the treatment of PSLI, PSEJ, and ESEJ MLD. 
  • Lenmeldy is a gene therapy utilizing autologous HSPCs enriched with CD34+ cells, then transduced ex vivo with an HIV-1-based LVV that has been modified to carry the ARSA cDNA sequence, driving ARSA enzyme production, leading to breakdown of sulfatides.
  • Lenmeldy is administered as a one-time IV infusion to add functional copies of the human ARSA gene into the patient’s HSPCs.
  • The FDA has implemented post-marketing requirements to evaluate long-term efficacy and safety related to gene therapies.
Policy Updates:
  • 09/01/2024 – New policy for Lenmeldy approved by WHA P&T Committee. (P&T, 08/20/2024)
References:
  1. Lenmeldy Prescribing Information. Orchard Therapeutics. Boston, MA. March 2024.

Last review date: September 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone